CN112691115A - 预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 - Google Patents
预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 Download PDFInfo
- Publication number
- CN112691115A CN112691115A CN202110135233.2A CN202110135233A CN112691115A CN 112691115 A CN112691115 A CN 112691115A CN 202110135233 A CN202110135233 A CN 202110135233A CN 112691115 A CN112691115 A CN 112691115A
- Authority
- CN
- China
- Prior art keywords
- arabinoxylan
- solution
- food
- use according
- konjac flour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000617 arabinoxylan Polymers 0.000 title claims abstract description 132
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 title claims abstract description 129
- 230000002496 gastric effect Effects 0.000 title claims abstract description 30
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 29
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 24
- 235000013312 flour Nutrition 0.000 claims abstract description 23
- 229920002752 Konjac Polymers 0.000 claims abstract description 22
- 239000000252 konjac Substances 0.000 claims abstract description 20
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 19
- 235000010485 konjac Nutrition 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 15
- 239000003513 alkali Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 5
- 239000012535 impurity Substances 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 11
- 229920002581 Glucomannan Polymers 0.000 claims description 11
- 229940046240 glucomannan Drugs 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000000909 electrodialysis Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000021581 juice product Nutrition 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- 239000010902 straw Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002386 leaching Methods 0.000 abstract description 2
- 241001312219 Amorphophallus konjac Species 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
- 230000006378 damage Effects 0.000 description 35
- 241000700159 Rattus Species 0.000 description 27
- 210000001156 gastric mucosa Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 208000014674 injury Diseases 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000004062 sedimentation Methods 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000035622 drinking Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004357 Transferases Human genes 0.000 description 4
- 108090000992 Transferases Proteins 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- HMFHBZSHGGEWLO-QMKXCQHVSA-N alpha-L-arabinofuranose Chemical compound OC[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-QMKXCQHVSA-N 0.000 description 3
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- 150000004783 arabinoxylans Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- -1 small-molecule organic acids Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000909131 Homo sapiens Cytochrome P450 2E1 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003616 gastrointestinal mucosa protective agent Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了***木聚糖或其与魔芋粉的复合物在制备预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品中的应用。所述***木聚糖由植物性原料经预处理除杂质后进行碱液浸提、脱碱纯化制得。在***木聚糖与魔芋粉的复合物中,***木聚糖的质量占比为1~99%。本发明由***木聚糖单独或***木聚糖与魔芋粉的复合物制备得到的用于预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品,能有效减轻酒精对胃肠粘膜及肝脏的损伤。
Description
技术领域
本发明属于医药和食品技术领域,具体是预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物。
背景技术
饮酒是一种传统的人群偏好,且逐渐具有了社会交往属性,但过量饮酒不仅可以引起肝脏损害,而且对血液、消化、心血管和中枢神经***等均有不同程度的损伤。酒精是一种有机溶剂,容易透过生物膜,可通过呼吸道、消化道粘膜吸收,很少一部分由皮肤和其他粘膜吸收,吸收的速度和程度取决于吸收部位的酒精浓度梯度、膜的通透性和局部血流量。
肝脏是酒精代谢的主要器官,机体摄入的酒精90%以上在肝脏代谢,乙醇进入肝脏后,经过乙醇脱氢酶(ADH)、肝微粒体乙醇氧化酶***(MEOS)和过氧化氢酶氧化成乙醛。酒精性肝损伤(alcoholicliverdamage)是由长期或大量饮酒导致的肝脏疾病,初期表现为脂肪肝,进而可发展成酒精性肝炎、肝纤维化和肝硬化,严重者可诱发肝癌和肝功能衰竭,已被西方国家列为因肝脏疾病引发的死亡的主要原因之一。酒精代谢过程的第一步(即将乙醇代谢为乙醛的步骤)主要通过两种氧化体系来实现,其中一种为胞质内乙醇氧化体系,摄入体内的乙醇大约有80%经该体系代谢,另一种为内质网内微粒体乙醇氧化体系(microsomalethanoloxidizingsystem,MEOS),摄入体内的乙醇大约有20%经该体系代谢。MEOS中参与乙醇代谢的酶主要是细胞色素P4502E1(cytochromeP4502E1,CYP2E1),长期饮酒可对其产生明显的诱导作用。当乙醇浓度较低时,主要被胞质内乙醇氧化体系催化分解;若乙醇浓度过高,则需同时借助于MEOS进行代谢。长期饮酒所导致的体内高浓度乙醇会诱导MEOS中关键酶CYP2E1的大量表达,此时乙醇主要由MEOS代谢,进而产生大量的活性氧自由基,这正是乙醇导致肝损伤的重要机制之一。
胃肠道也参与酒精代谢,胃肠道粘膜自身对酒精具有一定代谢能力,称为首过代谢(FPM),维护正常的胃肠粘膜功能,增加酒精与胃肠粘膜乙醇脱氢酶(ADH)的作用时间有利于增强首过代谢水平,降低血液酒精浓度(SEC)。酒精进入肠道被微生物代谢为乙醛,乙醛会增加胃肠道细胞通透性,提高肠源性内毒素渗漏至肝脏血液循环的几率,形成二次攻击,加重肝损伤。另外,小肠对内毒素和细菌等致病因子的高通透性还会导致机体发热、白细胞增多、微循环障碍、休克、多器官功能衰竭等。因此,虽然与肝脏相比,酒精在胃肠道的代谢要少得多,但胃肠粘膜保护对减少酒精性肝脏损伤依然具有重要意义。
***木聚糖(AX)是谷物外层和胚乳细胞壁中一种重要的功能性半纤维素,AX主要分布于小麦、大麦、燕麦、稻米、高粱以及谷子等粮食作物,此外在亚麻籽和香蕉皮等作物中的含量也很丰富。AX的结构是由以β-D-吡喃木糖残基经β-(1→4)糖苷键连接而成的木聚糖为主链,α-L-呋喃***糖为侧链连接而成。β-D-木糖残基可在C2和C3位被α-L-呋喃***糖单取代,也可在C2和C3位同时被α-L-呋喃***糖双取代。另外,在某些***糖基的C5位上存在着以酯键相连接的阿魏酸,这种***糖基通常连接在木糖残基的C3位上,阿魏酸的存在对于AX的功能特性有重要的作用。***木聚糖结构特征的一个重要指标是其木聚糖主链的平均取代度,即Ara/Xly(A/X)及***糖残基的相对数量和取代情况的不同;这是造成***木聚糖溶解性、溶液粘度、胶凝性、酶作用程度等性质差异的主要原因。根据***木聚糖在水中溶解性质的差异分为水溶性***木聚糖(water solublearabinoxylan,WSAX)和水不溶性***木聚糖(water insoluble ar—abinoxylan,WISAX),与WSAX相比,WISAX的分子量较大,支链程度高(***糖和木糖比值较低),阿魏酸含量较高。AX能很好地改善面团的性质和面包的烘焙质量,可将其开发为增稠剂、保湿剂和面包添加剂等。AX具有诸多重要的生理功能;作为膳食纤维,具有润肠通便、减肥美容之功效;作为免疫调节剂,可启动自然杀伤(NK)细胞、T和B淋巴细胞,增强人体免疫功能;另外,AX还具有调节血糖水平、降血脂、抗氧化、促进肠道蠕动、抗肿瘤、提高免疫活性等多种生理功能。但是,目前还没有关于将***木聚糖用于预防/治疗酒精性胃肠粘膜和肝脏损伤的报道。
水提取、化学提取、酶提取和机械辅助提取已经广泛的应用于AX生产中,依据AX提取得率而言,碱溶剂法和机械辅助法具有更高的提取效率,但由于成本、仪器安全和环境等问题很难应用于工业生产中;酶法得率较低,但是可与机械辅助法、化学溶剂法相结合提高AX得率;机械辅助法具有提高AX得率的作用,其中蒸汽***法和挤压法均具有环境友好型优点,适合工业生产。现有对AX的研究还集中在得率、纯度等工艺条件以及肠道微生态、生理代谢、机体免疫功能干预等方面,而AX或其复合物用于预防/治疗酒精性胃肠粘膜和肝脏损伤保护功能的研究还未见报道。
发明内容
本发明的目的是针对现有技术的不足,提供一种预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物,并明确指出由***木聚糖单独或***木聚糖与魔芋粉的复合物制备得到的用于预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品,能有效减轻酒精对胃肠粘膜及肝脏的损伤。
***木聚糖或其与魔芋粉的复合物在制备预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品中的应用。
在***木聚糖与魔芋粉的复合物中,***木聚糖的质量占比为1~99%。
优选地,所述***木聚糖中聚糖含量>60%。
优选地,所述魔芋粉中葡甘露聚糖含量>60%。
以上所述***木聚糖由植物性原料经预处理除杂质后进行碱液浸提、脱碱纯化制得。
以上所述植物性原料包括半纤维素成分以***木聚糖为主的秸秆、玉米芯、麸糠或木材等中任意一种以上。
优选地,所述***木聚糖的具体制备方法如下:
(1)将植物性原料粉碎后,加入8~12倍重量、质量浓度为0.2~1.0%的NaOH溶液,在40~90℃保温处理1.5~2.5h,再用清水置换洗涤然后过滤脱水,得到洁净纤维。
(2)向以上得到的洁净纤维中加入6~10倍重量、质量浓度为8~12%的NaOH溶液,在55~65℃下保温提取5.5~6.5h,沉降离心收集一级上清液,残渣再用8~12倍重量、质量浓度为3~5%的NaOH溶液进行连续逆流置换,置换液沉降离心后收集二级上清液,合并一、二级上清液,得到***木聚糖碱溶液。
(3)***木聚糖碱溶液经脱碱处理后,加酸中和至pH6.0~8.0,浓缩脱水,再加清水进行连续置换脱盐处理,干燥,即得。
优选地,以上步骤(2)第一次沉降离心采用卧式螺旋沉降离心机,第二次沉降离心采用分离因数更高的蝶式离心机。
以上步骤(3)脱碱方式可以采用超滤膜过滤方式或电渗析膜置换方式中任意一种或两种组合。优选地,超滤膜截留分子量≤10kDa。
以上步骤(3)所用酸为盐酸、柠檬酸或醋酸中任意一种,质量浓度为4~6%。
以上步骤(3)浓缩脱水采用超滤膜过滤方式进行浓缩;优选地,超滤膜截留分子量≤10kDa。
***木聚糖单独或***木聚糖与魔芋粉的复合物选择性添加常规辅料,按照常规工艺制成冲剂、粉剂、片剂、胶囊剂或混悬剂等任何可接受的剂型,作为普通食品、保健食品或药品。
***木聚糖单独或***木聚糖与魔芋粉的复合物添加到任意其它加工食品或食品原料当中,通过不同食品载体发挥功能。所述的不同食品载体包括米、面制品,乳制品,植物蛋白制品和干、鲜果汁制品等。
本发明的有益效果是:
在本发明中限定了***木聚糖中聚糖含量>60%,魔芋粉中葡甘露聚糖含量>60%,其中,***木聚糖可以是市售的***木聚糖,也可以是根据本发明的制备方法制备得到的***木聚糖。***木聚糖是由β-D-吡喃木糖残基经β-( 1→4)糖苷键连接构成聚糖主链,同时还连接有***糖、葡萄糖醛酸等基团为支链的聚糖类;当***木聚糖中聚糖含量>60%时,***木聚糖含有大量的水不溶性***木聚糖,保持着***木聚糖的天然大分子特性,可均匀分散于水中,随pH值降低粘度加大,甚至呈凝胶状,难以被胃酸分解破坏,对胃及小肠内环境影响也很小。稳定的物化特性和优异的生理功能使得该***木聚糖具备开发为新型胃肠粘膜保护剂的潜力。魔芋粉是从魔芋中提取得到的,主要成分是由甘露糖和葡萄糖两种糖基以β-( 1→4) 糖苷键聚合成主链的聚糖,称为葡甘露聚糖。葡甘露聚糖具有亲水、增稠、稳定、乳化、悬浮、凝胶和成膜等多种特性,与***木聚糖类似,由于缺乏相应降解酶,葡甘露聚糖在胃和小肠中稳定性好,可在胃肠粘膜表面展开并形成类粘膜保护层,减少酒精直接对粘膜的接触和刺激;因此,本发明限定魔芋粉中葡甘露聚糖含量>60%,有利于提高复合物对于胃肠粘膜的保护作用。
在本发明***木聚糖的制备方法中,通过稀碱低温预处理深度净化提取原料,食品安全性高,所获得的***木聚糖也是一种高纯度大分子多糖,同时包含了水溶性***木聚糖和水不溶性***木聚糖,***木聚糖中可水解聚糖含量高达80%以上,极大地保持了***木聚糖的天然大分子特性,对于胃肠粘膜的保护作用强。
本发明的***木聚糖还具有减慢胃排空速度的作用,有利于提高首过代谢水平,降低血液酒精浓度,同时兼具膳食纤维的诸多生理功能。本发明将***木聚糖制备成可用于预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品,适用于长期饮酒或服药所引起的胃肠粘膜和肝脏损伤的预防或治疗。***木聚糖与魔芋粉的复合物又比单独使用***木聚糖的疗效更加显著,可达到与阳性药物奥美拉措效果接近甚至更佳水平。
***木聚糖和葡甘露聚糖在肠道中经特定微生物发酵后,高产乙酸、丙酸、丁酸等短链脂肪酸,并通过这些小分子有机酸参与代谢、神经和免疫***调控。其中丁酸是消化道上皮细胞的能源物质,可修复受损消化道上皮细胞,有效抑制消化道炎症反应的发生和发展。乙酸水平则与肝、肾等器官炎症性指标呈负相关,丙酸参与肝脏脂质代谢调控,具有提高胃肠壁上皮组织抗氧化酶活性、预防脂肪肝及改善胃肠粘膜***功能。***木聚糖还能够增殖多种已知的肠道益生菌,这些益生菌能有效降低氨类、酚类、吲哚类等肠源性内毒素产生,并起到润肠通便、提高免疫力的功效。此外,***木聚糖是人类农耕文明以来伴随谷物主粮长期大量摄入的营养成分,对绝大多数药物干扰可能性极低,可与其他胃粘膜和肝脏保护药物混合使用提升效果。
附图说明
图1是正常对照组、模型对照组、阳性对照组大鼠胃粘膜损伤情况代表图;
图2是***木聚糖低剂量组、***木聚糖高剂量组、***木聚糖复合物①组、***木聚糖复合物②组大鼠胃粘膜损伤情况代表图;
图3是模型对照组、***木聚糖高剂量组、***木聚糖复合物①组、***木聚糖复合物②组大鼠胃粘膜损伤情况病理切片图。
具体实施方式
为了更加详细的介绍本发明,下面结合实施例,对本发明做进一步说明。
实施例1
***木聚糖的具体制备方法如下:
(1)选取干燥无霉变谷物麸皮10kg,加入100kg质量浓度为0.2%的NaOH溶液,在40℃保温处理2h,再用清水置换洗涤然后过滤脱水,得到洁净纤维。
(2)向以上得到的洁净纤维中加入80kg质量浓度为8%的NaOH溶液,在60℃下保温提取6h,提取液用卧式螺旋沉降离心机进行沉降离心收集一级上清液,残渣再用100kg质量浓度为4%的NaOH溶液进行连续逆流置换,置换液用蝶式离心机进行沉降离心收集二级上清液,合并一、二级上清液,得到***木聚糖碱溶液165kg。
(3)***木聚糖碱溶液经超滤膜脱碱处理后,边搅拌边缓慢加入质量浓度为5%的盐酸中和至pH6.0~8.0,用超滤膜进行浓缩脱水,再加清水进行连续置换脱盐处理,喷雾干燥,得到***木聚糖1.1kg。所述超滤膜截留分子量≤10kDa。最终得到的***木聚糖中可水解聚糖含量为82%,各项污染物指标均在谷物类食品国家标准范围内。
实施例2
***木聚糖的具体制备方法如下:
(1)选取干燥无霉变经粉碎后的玉米芯1kg,加入10kg质量浓度为1.0%的NaOH溶液,在90℃保温处理2h,再用清水置换洗涤然后过滤脱水,得到洁净纤维。
(2)向以上得到的洁净纤维中加入8kg质量浓度为10%的NaOH溶液,在60℃下保温提取6h,提取液用卧式螺旋沉降离心机进行沉降离心收集一级上清液,残渣再用10kg质量浓度为4%的NaOH溶液进行连续逆流置换,置换液用蝶式离心机进行沉降离心收集二级上清液,合并一、二级上清液,得到***木聚糖碱溶液16kg。
(3)***木聚糖碱溶液经电渗析膜置换脱碱处理后,边搅拌边缓慢加入质量浓度为5%的柠檬酸中和至pH6.0~8.0,用截留分子量≤10kDa的超滤膜进行浓缩脱水,再加清水进行连续置换脱盐处理,喷雾干燥,得到***木聚糖0.17kg。最终得到的***木聚糖中可水解聚糖含量为88%,各项污染物指标均在谷物类食品国家标准范围内。
实施例3
预防/治疗胃肠粘膜和肝脏损伤的***木聚糖复合物①由实施例1的***木聚糖80重量份、葡甘露聚糖含量为85%的市售魔芋精粉20重量份混合得到。
预防/治疗胃肠粘膜和肝脏损伤的***木聚糖复合物②由实施例1的***木聚糖95重量份、葡甘露聚糖含量为85%的市售魔芋精粉5重量份混合得到。
预防/治疗胃肠粘膜和肝脏损伤的***木聚糖复合物③由实施例2的***木聚糖80重量份、葡甘露聚糖含量为85%的市售魔芋精粉20重量份混合得到。
预防/治疗胃肠粘膜和肝脏损伤的***木聚糖复合物④由实施例2的***木聚糖95重量份、葡甘露聚糖含量为85%的市售魔芋精粉5重量份混合得到。
为了验证本发明的***木聚糖或***木聚糖与魔芋粉的复合物在预防酒精性胃肠粘膜和肝脏损伤方面的功效,本申请人进行了以下试验:
试验对象:SD大鼠,雌性,6周龄,体重200g~220g/只,共56只,购自湖南省斯莱克景达试验动物有限公司,许可证号:SCXK(湘)2019-0004。
对大鼠进行适应性喂养3天,随机分为7组,正常对照组、模型对照组、阳性对照组、***木聚糖低剂量组、***木聚糖高剂量组、***木聚糖复合物①组、***木聚糖复合物②组。阳性对照组每天灌胃给予奥美拉措40mg/kg,***木聚糖低剂量组每天灌胃给予实施例1制备得到的***木聚糖1g/kg,***木聚糖高剂量组每天灌胃给予实施例1制备得到的***木聚糖1.5g/kg,***木聚糖复合物①组每天灌胃给予***木聚糖复合物①1g/kg,***木聚糖复合物②组每天灌胃给予***木聚糖复合物②1g/kg,正常对照组、模型对照组灌胃给予生理盐水,灌胃容量4mL/只,试验期间自由饮水,使用大鼠标准维持颗粒饲料饲喂。
连续给药14天后,所有大鼠禁食24h,禁食期间自由饮水。***木聚糖复合物②组按照以上剂量连续灌胃14天后,禁食24h,在用酒精处理前1h再灌胃给予***木聚糖复合物②一次。除正常对照组外,其它各组灌胃给予无水乙醇诱导胃损伤,1.0mL/只。无水乙醇灌胃1h后,于颈动脉取血清,测定血清中的ALT(丙氨酸转移酶)和AST(天门冬氨酸转移酶)的含量,结果见表1。取血后将所有大鼠颈椎脱臼处死,取胃,沿胃大弯切开,PBS清洗,展开胃粘膜,用纸吸干水分,仔细观察胃粘膜层损伤情况,各试验组大鼠胃粘膜损伤情况代表图见图1-2。同时记录出血点数,用游标卡尺测量溃疡条纹的长度和宽度,根据国家食品药品监督管理局(CFDA出版物第107号,2012年修订)标准计算溃疡程度的宏观评价评分表对胃病变进行组织学评分,计算各组大鼠的损伤发生率和损伤抑制率,胃粘膜损伤评分标准见表2,损伤发生率和损伤抑制率见表3。
组织学评分后将每只胃切成两半,用一半胃进行组织匀浆检测胃粘膜组织中SOD、MDA含量(若没办法立刻匀浆检测可先保存在-80℃),并计算胃粘膜损伤指数,损伤指数结果见表4。将另一半胃上胃粘膜损伤最严重的部位切下,然后按照以下步骤进行处理制备HE染色切片并观察切片病变情况(若没办法立刻进行处理可先将切下的损伤部位固定于中性***溶液中):
(1)将每个组织按照以下步骤进行脱水:50%乙醇(90min)→70%乙醇(90min)→85%乙醇(90min)→95%乙醇(90min)→100%乙醇(60min)→100%乙醇(60min)。
(2)将脱水后的组织按照以下步骤进行透明:1/2乙醇+1/2二甲苯→二甲苯→二甲苯,每步60min。
(3)将透明后的组织按照以下步骤在62℃下进行浸蜡:1/2二甲苯+1/2石蜡(90min)→石蜡I(120min)→石蜡II(120min)。
(4)将组织放入盛有石蜡的模具中,摆好位置,倒入融化的石蜡,冷却。
(5)将包埋好的组织蜡块固定于切片机上切成约4μm厚的薄片,放于水浴锅中展开,再将切片捞于多聚赖氨酸附膜载玻片上,编号后在65℃干烤4h。
(6)采用HE染色试剂盒对切片进行HE染色,然后观察切片的病变情况。各组大鼠胃粘膜损伤情况病理切片图见图3。
损伤发生率、损伤抑制率和损伤指数的计算公式:
(1)损伤发生率(%)=某组出现出血或者溃疡大鼠数量/该组大鼠数量×100%
(2)损伤抑制率(%)=(A-B)/A×100%(A为模型对照组的损伤积分、B为其他各试验组的损伤积分)
(3)损伤指数=组损伤评分总和/组动物数量
血清中丙氨酸转移酶和天门冬氨酸转移酶是反映肝脏损伤程度的标注性酶,从表1可以明显看出,模型对照组大鼠酶指标严重升高,表示肝脏受损严重,而给予本发明的***木聚糖或其复合物的大鼠酶指标趋于正常,说明本发明的***木聚糖及其复合物对于酒精性肝脏损伤有保护作用。从表3中可以看出,乙醇能够明显引起大鼠胃粘膜出血,导致胃粘膜损伤,本发明的***木聚糖及其复合物均能够有效抑制酒精造成的大鼠胃粘膜损伤。从表4可以看出,本发明的***木聚糖及其复合物均可以显著降低乙醇对大鼠胃粘膜的损伤指数。从图1~2可以看出,本发明***木聚糖及其复合物能够显著减轻乙醇对大鼠胃粘膜造成的损伤程度。从图3可以看出,模型对照组大鼠胃粘膜上皮细胞变性坏死,出现炎症细胞浸润约占上皮的45~60%;***木聚糖高剂量组大鼠胃粘膜也出现炎症细胞浸润,但是损伤程度要比模型对照组小,其损伤部分约占上皮的14~29%;***木聚糖复合物①组和②组大鼠胃粘膜结构基本正常,少见炎症细胞浸润。通过整胃粘膜观察和HE染色切片观察得到的病理结果与大体(即整体)观察评分结果基本一致,可以判定本发明***木聚糖及其复合物对酒精性胃粘膜损伤有保护治疗作用。
根据食品药品监督管理局提供的《对胃粘膜损伤有辅助保护功能评价方法(征求意见稿)》中的规定:“受试物一个或一个以上剂量组与模型对照组进行比较,大体观察评分与病理组织学检查评分,结果均表明胃粘膜损伤明显改善,可判定该受试物杨平动物试验结果为阳性”,本试验大体观察评分效果明显,本发明的***木聚糖及其复合物能够降低大鼠胃粘膜损伤发生率,能够显著降低大鼠胃粘膜损伤指数、提高大鼠胃粘膜损伤抑制率,在病理上也得到支持,因此,可以判定本发明的***木聚糖及其复合物对胃粘膜有预防及辅助保护治疗作用。
本发明不局限于上述最佳实施方式,任何人在本发明的启示下都可得出其他各种形式的产品,但不论在其细节上作何种变化,凡是具有与本申请相同或相近似的技术方案,均落在本发明的保护范围内。
Claims (10)
1.***木聚糖或其与魔芋粉的复合物在制备预防/治疗酒精性胃肠粘膜和肝脏损伤的食品、保健品或药品中的应用。
2.根据权利要求1所述的应用,其特征在于,在***木聚糖与魔芋粉的复合物中,***木聚糖的质量占比为1~99%。
3.根据权利要求1或2所述的应用,其特征在于,所述***木聚糖中聚糖含量>60%。
4.根据权利要求1或2所述的应用,其特征在于,所述魔芋粉中葡甘露聚糖含量>60%。
5.根据权利要求1或2所述的应用,其特征在于,所述***木聚糖由植物性原料经预处理除杂质后进行碱液浸提、脱碱纯化制得。
6.根据权利要求5所述的应用,其特征在于,所述植物性原料包括半纤维素成分以***木聚糖为主的秸秆、玉米芯、麸糠或木材中任意一种以上。
7.根据权利要求5所述的应用,其特征在于,所述***木聚糖的具体制备方法如下:
(1)将植物性原料粉碎后,加入8~12倍重量、质量浓度为0.2~1.0%的NaOH溶液,在40~90℃保温处理1.5~2.5h,再用清水置换洗涤然后过滤脱水,得到洁净纤维;
(2)向以上得到的洁净纤维中加入6~10倍重量、质量浓度为8~12%的NaOH溶液,在55~65℃下保温提取5.5~6.5h,沉降离心收集一级上清液,残渣再用8~12倍重量、质量浓度为3~5%的NaOH溶液进行连续逆流置换,置换液沉降离心后收集二级上清液,合并一、二级上清液,得到***木聚糖碱溶液;
(3)***木聚糖碱溶液经脱碱处理后,加酸中和至pH6.0~8.0,浓缩脱水,再加清水进行连续置换脱盐处理,干燥,即得。
8.根据权利要求7所述的应用,其特征在于,步骤(3)脱碱方式可以采用超滤膜过滤方式或电渗析膜置换方式中任意一种或两种组合。
9.根据权利要求1所述的应用,其特征在于,***木聚糖单独或***木聚糖与魔芋粉的复合物选择性添加常规辅料,按照常规工艺制成冲剂、粉剂、片剂、胶囊剂或混悬剂,作为普通食品、保健食品或药品。
10.根据权利要求1或9所述的应用,其特征在于,***木聚糖单独或***木聚糖与魔芋粉的复合物添加到任意其它加工食品或食品原料当中,通过不同食品载体发挥功能;所述的不同食品载体包括米、面制品,乳制品,植物蛋白制品和干、鲜果汁制品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110135233.2A CN112691115A (zh) | 2021-02-01 | 2021-02-01 | 预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110135233.2A CN112691115A (zh) | 2021-02-01 | 2021-02-01 | 预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112691115A true CN112691115A (zh) | 2021-04-23 |
Family
ID=75516454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110135233.2A Pending CN112691115A (zh) | 2021-02-01 | 2021-02-01 | 预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112691115A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113796538A (zh) * | 2021-08-06 | 2021-12-17 | 上海赛普瑞特生物科技有限公司 | 水不溶性***木聚糖在制备预防癌症和提升自然杀伤细胞免疫活性药品或食品中的应用 |
CN113875871A (zh) * | 2021-10-11 | 2022-01-04 | 唐传生物科技(厦门)有限公司 | 一种健康糖 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004065156A (ja) * | 2002-08-08 | 2004-03-04 | Genmai Koso:Kk | 肝臓ガン発症抑制組成物の製造方法並びに組成物 |
CN101531722A (zh) * | 2009-04-16 | 2009-09-16 | 江苏康维生物有限公司 | 一种改进的碱法抽提制备植物木聚糖方法 |
CN102065847A (zh) * | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | 含有血管紧张素-ⅱ受体阻断剂的药物制剂 |
CN104431361A (zh) * | 2014-12-03 | 2015-03-25 | 中国人民解放军总后勤部军需装备研究所 | 小麦***木聚糖提取物在提高肠道屏障功能中的应用 |
CN105696396A (zh) * | 2016-03-24 | 2016-06-22 | 广西壮族自治区中国科学院广西植物研究所 | 一种从半纤维素提取液中分流回收半纤维素、木质素和碱液的方法 |
CN108359026A (zh) * | 2018-05-11 | 2018-08-03 | 桂林纤元生物技术有限公司 | 一种水不溶性木聚糖的制备方法及其用途 |
-
2021
- 2021-02-01 CN CN202110135233.2A patent/CN112691115A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004065156A (ja) * | 2002-08-08 | 2004-03-04 | Genmai Koso:Kk | 肝臓ガン発症抑制組成物の製造方法並びに組成物 |
CN102065847A (zh) * | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | 含有血管紧张素-ⅱ受体阻断剂的药物制剂 |
CN101531722A (zh) * | 2009-04-16 | 2009-09-16 | 江苏康维生物有限公司 | 一种改进的碱法抽提制备植物木聚糖方法 |
CN104431361A (zh) * | 2014-12-03 | 2015-03-25 | 中国人民解放军总后勤部军需装备研究所 | 小麦***木聚糖提取物在提高肠道屏障功能中的应用 |
CN105696396A (zh) * | 2016-03-24 | 2016-06-22 | 广西壮族自治区中国科学院广西植物研究所 | 一种从半纤维素提取液中分流回收半纤维素、木质素和碱液的方法 |
CN108359026A (zh) * | 2018-05-11 | 2018-08-03 | 桂林纤元生物技术有限公司 | 一种水不溶性木聚糖的制备方法及其用途 |
Non-Patent Citations (4)
Title |
---|
CAROLINE MELLINGER-SILVA,等: "Isolation of a gastroprotective arabinoxylan from sugarcane bagasse", 《BIORESOURCE TECHNOLOGY》 * |
付元芳,等: "***木聚糖对高脂日粮诱导大鼠脂质代谢和肝脏损伤的影响", 《2017年四川省食品与营养学术年会论文集》 * |
沈玖君,等: "魔芋粉对小鼠急性酒精性胃黏膜损伤和慢性酒精性肠损伤的影响", 《食品科学》 * |
黄利华,等: "根茎淀粉植物皮渣中膳食纤维的研究进展", 《广州城市职业学院学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113796538A (zh) * | 2021-08-06 | 2021-12-17 | 上海赛普瑞特生物科技有限公司 | 水不溶性***木聚糖在制备预防癌症和提升自然杀伤细胞免疫活性药品或食品中的应用 |
CN113875871A (zh) * | 2021-10-11 | 2022-01-04 | 唐传生物科技(厦门)有限公司 | 一种健康糖 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dou et al. | Digestive property and bioactivity of blackberry polysaccharides with different molecular weights | |
Nie et al. | Bioactive polysaccharides from Cordyceps sinensis: Isolation, structure features and bioactivities | |
JP4044599B2 (ja) | カワラタケ株及びその抽出物及びその利用 | |
CN108720030B (zh) | 一种靶向改善代谢综合征的膳食纤维组合物 | |
TW200904340A (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
CN112691115A (zh) | 预防/治疗胃肠粘膜和肝脏损伤的***木聚糖及复合物 | |
CN111040044B (zh) | 一种蛹虫草胞内多糖及制备方法及其在调节肠道菌群中的应用 | |
CN106213523A (zh) | 一种海芦笋膳食纤维的提取方法 | |
CN113480676B (zh) | 低聚半乳糖醛酸多糖、复合物及其制备方法和应用 | |
KR20140138490A (ko) | 꽃송이버섯 발효식품 및 그 제조방법 | |
CN110772630A (zh) | 活化胰岛素受体及调控血糖的复合苦瓜肽口服液及制备方法 | |
Zhou et al. | Fabrication of quercetin-loaded nanoparticles based on Hohenbuehelia serotina polysaccharides and their modulatory effects on intestinal function and gut microbiota in vivo | |
Lu et al. | Effects of exopolysaccharides from Antrodia cinnamomea on inflammation and intestinal microbiota disturbance induced by antibiotics in mice | |
CN113730444A (zh) | 一种海带中可溶性膳食纤维在制备用于改善溃疡性结肠炎的药物和功能性食品中的应用 | |
JPH03285653A (ja) | 脂質代謝改善物及びその製造法 | |
JP2012085591A (ja) | ダイエット食品 | |
JPWO2009078495A1 (ja) | 穀類植物種子由来の不溶性食物繊維含有物質 | |
CN114989258B (zh) | 植物提取组合物在制备治疗便秘、减肥产品上的应用 | |
CN114304640B (zh) | 一种保护胃黏膜的多糖组合物及其制备方法与应用 | |
JPH06247861A (ja) | 抗潰瘍剤およびその製造法 | |
WO2021174801A1 (zh) | 一种牛樟芝水不溶性膳食纤维的制备方法 | |
KR20110132887A (ko) | 간, 위 기능 및 숙취 개선용 조성물 | |
JP2001145472A (ja) | 大麦焼酎蒸留残液から分取した脂肪肝抑制作用を有する組成物及び該組成物の製造方法 | |
JP2008214246A (ja) | Age生成阻害剤およびその製造方法 | |
KR20110060002A (ko) | 숙취 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |